Modeling Glioma Growth and Invasion in Drosophila melanogaster  by Teresa Witte, Hanna et al.
Modeling Glioma
Growth and Invasion in
Drosophila melanogaster1
Hanna Teresa Witte*,†,2, Astrid Jeibmann*,†,2,
Christian Klämbt* and Werner Paulus†
*Institute of Neurobiology, University of Münster, Münster,
Germany; †Institute of Neuropathology, University Hospital
Münster, Münster, Germany
Abstract
Glioblastoma is the most common and most malignant intrinsic human brain tumor, characterized by extensive
invasion and proliferation of glial (astrocytic) tumor cells, frequent activation of tyrosine kinase receptor signaling
pathways, relative resistance to chemotherapy and radiotherapy, and poor prognosis. Using the Gal4-UAS system,
we have produced glioma models in Drosophila by overexpressing homologs of human tyrosine kinase receptors
under control of the glia-specific promoter reversed polarity (repo). Glial overexpression of activated epidermal
growth factor receptor (EGFR) resulted in enhanced proliferation and migration of larval glial cells with increased
numbers in the eye imaginal disc, diffuse tumor-like enlargement of the optic stalk, and marked ectopic invasion of
glial cells along the optic nerve. Glial overexpression of the downstream kinase PI3K showed similar pathology.
Overexpression of activated pvr (platelet-derived growth factor receptor/vascular endothelial growth factor recep-
tor homolog) led to migration of glial cells along the optic nerve, whereas expression of activated htl (fibroblast
growth factor receptor 1 homolog) and INR (insulin receptor) showed markedly elevated numbers of glial cells in
the optic stalk. The EGFR/phosphatidylinositol 3-phosphate kinase (PI3K) phenotype was partly reverted by the ad-
ministration of the EGFR tyrosine kinase inhibitor gefitinib and completely rescued by the PI3K inhibitor wortmannin
and the Akt inhibitor triciribine. We suggest that Drosophila models will be useful for deciphering signaling cascades
underlying abnormal behavior of glioma cells for genetic screens to reveal interacting genes involved in glioma-
genesis and for experimental therapy approaches.
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Introduction
Glioblastomas represent the most common and most malignant in-
trinsic human brain tumors. These astrocytic neoplasms are character-
ized by a high proliferative activity, diffuse invasion of brain tissue,
and relative resistance to conventional cytotoxic chemotherapy and
radiotherapy, leading to poor prognosis with median survival of 12
to 18 months [1]. New types of “personalized” therapies targeting the
underlying molecular alterations of individual glioblastomas have in-
creasingly been considered and used in ongoing clinical studies. Prom-
ising molecular targets for therapeutic intervention have included the
tyrosine kinase receptors epidermal growth factor receptor (EGFR),
platelet-derived growth factor receptor (PDGFR), and vascular endo-
thelial growth factor receptor (VEGFR) and their downstream signal-
ing cascades, the phosphatidylinositol 3-phosphate kinase (PI3K)/
AKTand Ras/mitogen-activated protein kinase pathways [2,3].
Experimental in vivo models of glioblastoma are required for evaluat-
ing new types of experimental therapies as well as for better understand-
ing the biology of these fatal neoplasms. Most models are based on
transplantation of glioma cell lines into mouse or rat brains or on the
use of transgenic mice developing gliomas [4–6]. Advantages of rodent
models include their wide distribution among institutions with accumu-
lated experience for decades, the existence of a blood-brain barrier, and
the possibilities of applying therapeutic agents and studying the inter-
action of tumor and brain tissue. However, there are potential problems
of rodent models, such as restrictions of host genotype (only syngenic or
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immunodeficient animals being susceptible to tumor growth), the arti-
ficial nature of tumorigenesis after transplantation, a high number of
genetic changes in tumor cells, the long duration of experiments, high
cost, and ethical considerations.
Drosophila melanogaster, as a model organism, offers several advan-
tages, including easy handling, rapid generation time, low cost, and a
wide armamentarium of genetic techniques [7]. Many molecular path-
ways are conserved between invertebrates and humans, such as tyrosine
kinase receptor signaling cascades. Furthermore,Drosophila can be used
in neuropharmacological experiments because this organism is amena-
ble to external/food application, inhalation, or injection of substances
in a large number of wild type or mutant animals [8–12]. Fly models
of the hereditary tumor syndrome tuberous sclerosis as well as neuro-
fibromatosis types 1 and 2 have been established [13–16]. Further-
more, several mutants interfering with asymmetric cell division of
neuroblasts exhibit neuronal/neuroblastic tumors that are referred to
as “hyperplastic” in case of preserved architecture such as malignant
brain tumor (l(3)mbt) [17] or “neoplastic” with loss of architecture
and invasion such as brain tumor (brat), raps, numb, pros, andmira [18].
The larval brain is composed of two hemispheres and the ventral gan-
glion where peripheral nerves originate (Figure 1A). In the Drosophila
central nervous system, approximately 10% of cells are of glial nature,
which are classified as either midline glia or lateral glia, the latter being
positive for the glial marker reversed polarity (repo) [19]. During larval
development, photoreceptor neurons are specified within the eye im-
aginal disc and project their axons along the basal surface of the disc
into the optic stalk, bridging the eye imaginal disc with the optic lobes.
Repo-positive glial cells that originate from the optic stalk populate the
eye disc in a stereotyped manner, so that the number of glial cells is
predictable at certain time points of development [20], and changes
of proliferation or migration are easily detectable. The larval visual sys-
tem is located adjacent to the eye imaginal disc and consists of a pair
of 12 cells, the Bolwig organs. These send axonal projections (Bolwig
nerves, BNs) that enter the brain through the optic stalks and are phys-
iologically not accompanied by glial cells [21,22], enabling convenient
detection of glial overmigration along these axonal projections.
Only very recently, we and others have started to explore the useful-
ness of Drosophila in modeling gliomas by inducing EGFR/PI3K sig-
naling in larval glia [23,24]. We here report that not only Drosophila
lines overexpressing EGFR and/or PI3K but also lines overexpressing
other tyrosine kinase receptors, including PDGFR/VEGFR, fibroblast
growth factor receptor (FGFR), and insulin receptor homologs, show
increased proliferation and/or overmigration of glial cells in larval eye
structures, recapitulating histologic key features of human gliomas.
Moreover, we demonstrate that these experimental gliomas can be re-
verted by drugs targeting the EGFR signaling pathway.
Materials and Methods
Fly strains and genetics
All crosses were performed on standard food at room temperature
unless indicated otherwise. We used fly strains repo Gal4 (III), gener-
ated by a randomGal4 P-element insertion into the repo locus [25],UAS
λtop, the activated form of torpedo/Eg fr [26,27], UAS λpvr, the consti-
tutively active form of pvr [28], as well asUAS λhtl [29].UAS PI3K 92E,
generated by P-element insertion, UAS INR, and UAS CD8GFP,
which targets green fluorescent protein to the plasma membrane, were
obtained from Bloomington Stock Center (Bloomington, IN).
Crossings
Flies homozygous forUAS λtop,UAS PI3K92E,UAS CD8GFP,UAS
λpvr, UAS λhtl, UAS INR and flies harboring UAS λtop as well as UAS
PI3K 92E were crossed against a stock carrying a repo Gal4 transgene.
Immunohistochemistry
Fluorescent immunostaining was performed on third instar larva
brains and eye imaginal discs. Specimens were mounted in Vectashield
(Vector Laboratories, Burlingame, CA). Anti-repo antibodies were
obtained from theDevelopmental Studies Hybridoma Bank (IowaCity,
IA). Rabbit andmouse anti-GFP (both 1:500; Invitrogen, Eugene, OR)
and goat anti-HRPCy5 (1:200; Dianova, Hamburg, Germany) antisera
were used according to the manufacturer’s instructions. Fixation and
treatment of tissues for immunohistochemistry were performed accord-
ing to standard procedures.
Cy2,Cy3, orCy5 (1:200;DianovaGmbH) andAlexa 488, 568, or 647
(1:500;Molecular Probes,Carlsbad,CA)were used as secondary antibodies.
Pharmacological Inhibition of Ectopically Expressed Genes
Substances used were gefitinib (Biomol, Hamburg, Germany),
wortmannin (Biaffin, Kassel, Germany), and triciribine (Biaffin). One
gram of Drosophila medium (Carolina Biological Supply, Burlington,
NC) was mixed with 5 ml of H2O. The inhibitors were made soluble
in 100 mM DMSO. Flies harboring double insertions UAS PI3K92E
and UAS λtop were set for 24 hours on normal food (at 25°C) and then
on prepared food for 24 hours (at 25°C). Effects of inhibition were
analyzed by immunohistochemistry.
Confocal Laser Scanning Microscopy and Cell Counting
Images were taken with a confocal laser scanning microscope
(Axiovert 200M or Axio Imager Z.1 with LSM 510 META scanning
module; Zeiss, Oberkochen, Germany). Numbers of repo-expressing
glial cells were scored in different developmental stages. Cell counts
were performed on confocal image stacks with sections taken at 0.6-μm
distance (resolution, 512 × 512 pixels; pinhole, 100 mm; scan speed, 8).
Glial nuclei were counted using a three-dimensional image processing
program (Volocity 4.0; Improvision,Waltham,MA). For each age group,
15 imaginal discs were investigated. Volocity quantitation was set with an
intensity range of 60 to 255 and aminimal volume of 25 μm3.Only com-
plete confocal stacks were counted. White/black balance was performed
using Photoshop 7.0 (Adobe, Dublin, Ireland).
Statistical Analysis
Quantitative data were expressed as arithmetic means ± SEM. One-
way analysis of variance was performed followed by Scheffé procedure;
P < .05 was considered significant. Statistical analysis was performed
using SPSS version 15.0 (SPSS, Inc, Chicago, IL).
Results
Ectopic Expression of Activated Egfr and PI3K92E in Eye
Imaginal Discs of Third Instar Larva
Activated Eg fr as well as activated Eg fr in combination with wild-
type PI3K was expressed in Drosophila glial cells using the Gal4/UAS
system and the repo promoter, directing expression to lateral glial cells.
Expression of λtop, the activated form of torpedo/Eg fr (top/Eg fr) led to
increased numbers of glial cells in the optic stalk (Figure 1C ). Over-
migration of glial cells along BNs of the third instar larva was also
observed (Figure 1D). Similarly, expression of PI3K 92E resulted in
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Figure 1. Eye imaginal discs of third instar larvae with overexpression of activated Egfr and/or wild-type PI3K in glial cells. Immunofluores-
cence staining of (A–H) eye imaginal discs of third instar larvae. Nuclei of glial cells are red (α-Repo), glial cytoplasms are green (α-GFP), and
photoreceptor neurons are blue (α-HRP). Images are projections of confocal image stacks. (A) Wild-type eye imaginal disc with optic stalk.
(C, E, G) Ectopic gene expression resulted in a thickened optic stalk due to increased numbers of glial cells (arrowheads). (B) Wild-type eye
imaginal disc with BN. (D, F, H) Ectopic gene expression resulted in overmigration of glial cells along BN (arrowheads).
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enlargement of the optic stalk and overmigration of glial cells along BN
(Figure 1, E and F). Ectopic coexpression of λtop and PI3K92E resulted
in thickening of the optic stalk (Figure 1G ) and in massive ectopic
migration along BN (Figure 1H ), being more pronounced than in
the single transgenic lines. Quantitative analysis revealed that glial over-
expression of λtop significantly increased glial cell number in the eye
imaginal disc in all stages in comparison to wild type (Figure 2). How-
ever, overexpression of PI3K 92E resulted in reduced glial cell numbers
in later stages of development (Figure 2), presumably because most glial
cells weremisplaced in optic stalk and BN.Consequently, no differences
with the wild type were established after activation of both λtop and
PI3K 92E with respect to the number of glial cells in the eye disc.
Pharmacologically Induced Inhibition of Ectopically
Activated Genes
To determine whether the effects of transgene overexpression
can be rescued by pharmacological inhibitors, we used flies simulta-
neously overexpressing UAS λtop and UAS PI3K 92E. First, the effect
of gefitinib (an EGFR-specific tyrosine kinase inhibitor) on the larval
eye imaginal disc was investigated. After applying the lowest concen-
tration (0.5 μM) of gefitinib in Drosophila food, the optic stalk was
still thickened, and large numbers of glial cells were migrating along
BN. Using the highest concentration of gefitinib (250 μM), the num-
ber of glial cells in the optic stalk remained high, whereas the number
of glial cells abnormally migrating along BN was considerably reduced
(Figure 3D).
Even at low concentrations (0.5 μM), the Akt inhibitor triciribine
markedly decreased glial overmigration along BN (Figure 3E), whereas
higher concentrations showed complete rescue (Figure 3, F–H ).
Low concentrations of 0.5 μM wortmannin (a specific PI3K inhib-
itor) were not sufficient to reduce optic stalk mass (Figure 3I), whereas
higher concentrations resulted in wild-type morphology optic stalks
(Figure 3, K and L). In contrast, BN (Figure 3, I–L) showed wild-type
configuration with all applied concentrations, indicating that even the
lowest concentration of wortmannin was sufficient to rescue abnormal
migration along BN.
Ectopic Expression of Other Receptor Tyrosine Kinases in
Eye Imaginal Discs of Third Instar Larva
To see whether the overexpression of other receptor tyrosine kinases
(RTKs) involved in gliomagenesis leads to similar results, activated
pvr, the Drosophila homolog of PDGFR/VEGFR, activated htl, the
Drosophila homolog of FGFR1, as well as INR, the Drosophila insulin
receptor, were expressed in Drosophila lateral glial cells under repo con-
trol. Overexpression of λpvr led to abnormal migration of glial cells
along BN (Figure 4A). Expression of λhtl and INR showed extensively
elevated numbers of glial cells in the optic stalk, whereas no or only
little overmigration along BN was observed (Figure 4, B and C).
Figure 2. Number of glial cells in different genotypes in eye imaginal discs of different age. Cell numbers expressing the glial marker repo
were morphometrically determined in different developmental stages. Age of imaginal discs was grouped according to rows of photo-
receptor neurons (0-5, 6-10, 11-15, 16-20 rows). In all investigated developmental stages, overexpression of λtop (activated Egfr) resulted in
increased glial cell numbers. In later stages, overexpression of PI3K92E led to a significant decrease of cell numbers (*P < .05).
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Figure 3. Effects of EGFR inhibitor gefitinib, Akt inhibitor triciribine, and PI3K inhibitor wortmannin on proliferation and migration induced by
ectopic expression of λtop and PI3K92E. Effects of gefitinib on eye imaginal disc of larvae were tested using genotype repo≫ λtop, PI3K92E.
Increasing concentrations of gefitinib reduced ectopic migration along BN (arrowheads; B, C, D), although the wild-type phenotype was not
reached. At low concentrations, the Akt inhibitor triciribine decreased glial migration along BN only partially (E, arrowhead), whereas higher
concentrations resulted in complete rescue (F–H). With increasing concentrations of the EGFR inhibitor wortmannin, optic stalks showed
complete rescue, corresponding to wild type. No overmigration along BNwas seen evenwith the lowest concentration of wortmannin (I–L).
M shows a wild-type eye imaginal disc.
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Discussion
We here describe invertebrate glioma models that are based on
the overexpression of tyrosine kinase receptors in Drosophila glia.
Morphologically, key features of human gliomas are recapitulated, such
as diffuse enlargement of brain structures due to single cell infiltration.
Invasion of brain structures along nerve tracts, which is a common
feature in human gliomas [30,31], is modeled in Drosophila larvae
by migration along optic nerves (BNs), which, in the wild type, is de-
void of glial cells, thereby facilitating detection of abnormal migration
because all glial cells along BN are invasive. Furthermore, invasion can
be easily quantitated by counting the number of glial cells in the BN
and by determining their distance from the eye imaginal disc. Because
of natural limitations of the species, including absence of blood vessels
and an adaptive immune system, other features of malignant gliomas
could not be reproduced, such as activated microglial cells and presence
of immune cells, vascular proliferation, and necrotic areas, the latter
being closely related to dysfunctional blood vessels in human gliomas.
Compared with most xenotransplantation models, our model is
more similar to human glioma specimens with respect to the typical
single-cell invasion pattern. Xenotransplanted glioma cell lines are
often cohesive and look like metastatic sarcomas, and despite common
claims, their invasion pattern is usually different from that of human
gliomas. The cells in our model show diffuse invasion, and they are
clearly glial so that the invasion pattern is more “human” than that
of many xenotransplants. However, although adhesion molecules of
glia and blood-brain barrier show considerable homologies between
Drosophila and vertebrates, almost nothing is known about the cerebral
extracellular matrix in Drosophila, which makes analysis of cell-matrix
interactions more difficult in our model.
EGFR is the most frequently amplified gene in glioblastoma. It
occurs in approximately 40% of primary glioblastomas and is associ-
ated with EGFR overexpression. Amplification of the EGFR gene is
often associated with structural alterations, the most common being
variant III (EGFRvIII), which is present in 20% to 50% of glioblasto-
mas with EGFR amplification and constitutively activated in a legend-
independent manner, leading to cell proliferation through PI3K, RAS,
and mitogen-activated protein kinase signaling pathways [1]. The PI3K
signaling cascade may also be activated by PTEN mutations in 15%
to 40% of primary glioblastomas and more infrequently by mutations
of the PI3K components PIK3CA [32] and PIK3R1 [33]. Because
more than 80% of glioblastomas show robust Akt activation, the
PI3K pathway is central in molecular pathogenesis. In fact, large-scale
multidimensional genomic characterization of 91 glioblastomas re-
vealed somatic alterations in RTK/PI3K pathways in 88% of tumors,
the genes most commonly involved being EGFR (45%), PTEN (36%),
and components of the PI3K complex (15%) [33]. In vitro evidence
suggests that activation of EGFR inhibits apoptosis and promotes in-
vasion of glioma cells [34,35].
Our data show that overexpression of activated EGFR or PI3K in
Drosophila is sufficient to produce tumor-like overgrowth and invasion
of glial cells. Furthermore, our findings demonstrate that in addition
to EGFR/PI3K, overexpressing other RTK receptors involved in glio-
magenesis leads to glioma-like lesions in Drosophila. Because the num-
ber of glial cells in the eye imaginal disc was increased after EGFR
expression, but decreased after PI3K expression and unchanged after
coexpressing EGFR and PI3K, our findings suggest that there are
additional signaling pathways upstream of PI3K regulating directed
migrating of glial cells. They also suggest that mutations in the same
signaling cascade are not necessarily associated with identical conse-
quences on cell biology, such as migration. It might be interesting to
compare the invasion patterns of human glioblastomas with EGFR
amplification to those with mutations of PI3K components.
New types of molecular therapies targeting EGFR or PI3K have re-
cently evolved as promising experimental and clinical approaches in
treating glioblastomas. Response of glioblastoma patients to the EGFR
inhibitor erlotinib was associated with EGFR expression/amplification
Figure 4. Eye imaginal discs of third instar larvaewith overexpression
of other tyrosine kinase receptors in glial cells. Immunofluorescence
staining of (A–C) eye imaginal discs. Nuclei of glial cells are red
(α-Repo), glial cytoplasms are green (α-GFP), and photoreceptor neu-
rons are blue (α-HRP). Images are projections of confocal image
stacks. (A) Ectopic gene expression of activated pvr, the Drosophila
homolog of PDGFR/VEGFR, resulted in overmigration of glial cells
along BN. (B and C) Ectopic gene expression of λhtl (homolog of acti-
vated FGFR1) and INR (insulin receptor) resulted in a thickened optic
stalk due to increased numbers of glial cells.
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and coexpression of EGFRvIII and PTEN in biopsy specimens [36,37].
However, only 10% to 20% of patients benefit from EGFR inhibition
[38], pointing to confounding factors such as coactivation of multiple
RTKs, thereby limiting the effects of therapies targeting single RTK. In
fact, combined treatment with several RTK inhibitors was more suc-
cessful [39]. Furthermore, glioblastomas harbor a variety of additional
genetic changes that may interact with RTK targeting. Drosophila lines
showing several coactivated RTK and inactivated tumor suppressor
genes in glial cells can be produced to better model genetic changes
typically encountered in glioblastomas. These invertebrate models
can then be used for large-scale genetic screens in detecting interacting
genes and for novel molecular-based experimental approaches.
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